Navigation Links
Pivotal MIRCERA(R) Study First to Convert Dialysis Patients From Frequent Dosing Directly to Once Every Two Weeks or Once Every Four Weeks
Date:10/19/2007

- MAXIMA findings in The Lancet affirm the maintenance of hemoglobin levels

with less frequent dosing -

NUTLEY, N.J., Oct. 19 /PRNewswire/ -- A pivotal study published today in The Lancet has shown that dialysis patients were effectively switched from frequently-dosed anemia drugs to an innovative investigational anemia treatment, MIRCERA(R), administered up to once every four weeks(1)

The MAXIMA study is the first randomized, comparative study to investigate the direct conversion of dialysis patients with chronic kidney disease from treatment with erythropoiesis-stimulating agents (ESA) given one to three times a week to IV MIRCERA administered once every two weeks or once every four weeks. The results demonstrated that MIRCERA maintained hemoglobin (Hb) concentrations within the target range as effectively as ESAs epoetin alfa or beta, which are typically given three times a week.

"Our findings demonstrate that MIRCERA was administered up to once every four weeks in hemodialysis patients without sacrificing hemoglobin stability," said Nathan Levin, M.D., Medical and Research Director, Renal Research Institute, New York, New York, and the lead author of the publication. "We note in The Lancet that these results should be generalizable to the maintenance hemodialysis population and that we believe this drug should be an option to epoetin for simplified anemia management."

About the MAXIMA Study

The MAXIMA study randomized 673 adult patients with stable chronic renal anemia on dialysis therapy and IV maintenance epoetin at 91 centers in eight countries. Most patients were from North America (U.S. - 68 percent; Canada - 11 percent) and Europe (21 percent). The study compared two administration intervals of IV MIRCERA (once every two weeks or once every four weeks) with continued IV epoetin treatment (one to three-times a week) in patients with chronic renal anemia. After a run-in period, patients were randoml
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
2. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
3. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
4. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
5. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
6. Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
7. Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial Data
8. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial as Compared to Neostigmine
9. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial Compared to Neostigmine
10. Pivotal Phase III Trial Showed Promacta (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP
11. Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... KONG and FT LAUDERDALE, Florida ... Inc. ("OrbusNeich"), a designer, developer, manufacturer and marketer of innovative ... that on May 13, 2015, it prevailed in a final ... European Patent EP 1 341 482 - STENT HAVING HELICAL ... of review in the EPO and has been upheld as ...
(Date:7/1/2015)... , July 1, 2015  Imprimis Pharmaceuticals, Inc. ... on the development and commercialization of proprietary compounded ... ring The Nasdaq stock market closing bell on ... growing success of its Go Dropless™ campaign since ... cataract procedures are performed annually in the U.S. ...
(Date:7/1/2015)...  LabStyle Innovations Corp. (DRIO), developer of the ... of Todd Durniak as Senior Vice President and General ... over 20 years of medical device commercial and ... and General Manager of Neighborhood Diabetes, a division ... durable medical equipment (DME) and pharmacy channels with ...
Breaking Medicine Technology:OrbusNeich Announces Favorable Ruling from the European Patent Office and Initiation of Litigation Against Terumo Corporation 2Imprimis Pharmaceuticals to Ring The Nasdaq Stock Market Closing Bell 2Imprimis Pharmaceuticals to Ring The Nasdaq Stock Market Closing Bell 3Imprimis Pharmaceuticals to Ring The Nasdaq Stock Market Closing Bell 4LabStyle Innovations Appoints Senior VP & General Manager in U.S. for the Dario Diabetes Management Solution 2LabStyle Innovations Appoints Senior VP & General Manager in U.S. for the Dario Diabetes Management Solution 3LabStyle Innovations Appoints Senior VP & General Manager in U.S. for the Dario Diabetes Management Solution 4
... SILVER SPRING, Md., Oct. 7, 2011 The U.S. ... simvastatin), a fixed-dose combination (FDC) prescription medication that contains ... in adults who need both sitagliptin and simvastatin. ... million people in the United States have type 2 ...
... Oct. 7, 2011 ProteinSimple today announced plans ... service support for its biologics products in Europe, ... are included in this expanded support structure:  iCE ... systems. The biologics market segment is ...
Cached Medicine Technology:FDA Approves Combination Therapy Juvisync 2FDA Approves Combination Therapy Juvisync 3ProteinSimple to Offer Direct Sales, Service and Support for Biologics Products in Europe 2
(Date:7/1/2015)... ... ... As if mood swings, cramps and child labor weren’t enough to endure, there ... Houston Vein Center is offering tips on the treatment options for women with leg ... often overlooked. Many women experience the tiredness, achiness, restless legs, cramps and itchiness related ...
(Date:7/1/2015)... ... July 01, 2015 , ... Trevor L. Williams, DMD holds ... and continued at USF earning a Master’s degree in Microbiology. He graduated from the ... the American Dental Association, the Florida Dental Association and the Academy of General Dentistry. ...
(Date:7/1/2015)... ... July 01, 2015 , ... Element Blue ... announced today that it has received trademark protection for its SensorInsight® computer software ... of data from multiple sources providing an environment where users can view and ...
(Date:7/1/2015)... ... July 01, 2015 , ... A Priority Setting Partnership put ... ten list they hope will guide future mesothelioma research. Surviving Mesothelioma has just ... , More than 450 mesothelioma patients, caregivers, and healthcare professionals answer ...
(Date:7/1/2015)... New York (PRWEB) , ... July 01, 2015 , ... Author Francesca Camp ... surgery fell into her lap, so too did her support of the practice; a terrible ... , In her new book, “Do I Need It ? (And What if ...
Breaking Medicine News(10 mins):Health News:Northeast Houston Vein Center Offers Tips for Women with Leg Pain 2Health News:Northeast Houston Vein Center Offers Tips for Women with Leg Pain 3Health News:Trevor L. Williams, D.M.D. Joins Enlow & Vance Dental Partners in Tampa, Florida 2Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 2Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 3Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 4Health News:New Report Identifies Top 10 Mesothelioma Research Priorities, According to Surviving Mesothelioma 2Health News:Francesca Camp’s New Book Unmasks Plastic Surgery Advice 2
... Nordisk Friday said the European Commission (EC) had approved its ... ,According to a company statement here, the EC ... in pregnant women with type 1 diabetes. ,"NovoRapid ... pregnancy in the European Union. The trial, which involved 322 ...
... needle experience fewer reactions but get the same protection ... on bmj.com// today. ,In the UK, primary ... 4 months of age. Despite recommendations for use of ... infants using a narrow-short (25G, 16mm) needle and uncertainty ...
... phenomenon, thanks to climatic changes, and what better way to ... of your favorite brand// of chilled soft drink. Indulging excessively ... the ever-increasing band of the young, the not- so- young, ... need to replace callousness with caution as the day of ...
... bold and dynamic methodology towards the usage of HIV drugs ... virus. ,Dr. Julio Montaner, the director of the ... with a perspective article that appears in tomorrow’s special issue ... research. ,Dr. Montaner said, “This is a mathematical ...
... products help diabetes in mice, according to a Penn researcher.// ... could make way for treating the condition without the need ... in dairy products such as milk, cheese and meat, and ... – fatty acids from plants – and convert them into ...
... Jennifer J. Vasterling of the Southeast Louisiana Veterans Health Care ... returning from Iraq showed mild problems with mental functioning. ... difficulty in focusing on a particular issue. ,They ... their return from Iraq. ,They lacked the ...
Cached Medicine News:Health News:Longer Needles Best for Infant Immunisation 2Health News:'Bottled' Contamination And a Brewing Battle 2Health News:Large Scale Free Access On Usage Of HIV Drugs Could Help In Fighting Its Spread 2Health News:CLA Compounds Fight Diabetes 2
Inquire...
Inquire...
... anti-reflux valve is enclosed in ... prevents the valve from being ... sitting or reclining positions. The ... interference free ensuring uninterrupted flow ...
... valve is enclosed in a ... the valve from being accidentally ... or reclining positions. The valve ... free ensuring uninterrupted flow and ...
Medicine Products: